{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:04:59Z","timestamp":1789743899038,"version":"4.0.1"},"reference-count":44,"publisher":"Norwegian Medical Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"DOI":"10.4045\/tidsskr.25.0555","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:45:14Z","timestamp":1775742314000},"source":"Crossref","is-referenced-by-count":0,"title":["Vaccination of immunosuppressed patients"],"prefix":"10.4045","volume":"146","author":[{"given":"Marton","family":"K\u00f6nig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trygve","family":"Holm\u00f8y","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gro Owren","family":"Nygaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Riise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Midtvedt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guro L\u00f8vik","family":"Goll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3693-7706","authenticated-orcid":false,"given":"Kristin Kaasen","family":"J\u00f8rgensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludvig A.","family":"Munthe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rre","family":"Fevang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders Eivind","family":"Myhre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Tr\u00f8seid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"ref=1","unstructured":"Folkehelseinstituttet. Voksenvaksinasjonsprogrammet \u2013 h\u00e5ndbok for helsepersonell 2025. https:\/\/www.fhi.no\/va\/vaksinasjonshandboka\/vaksinasjon\/voksenvaksinasjonsprogrammet\/ Lest 9.1.2026."},{"key":"ref=2","unstructured":"Folkehelseinstituttet. Vaksinasjon ved immunsvikt 2025. https:\/\/www.fhi.no\/va\/vaksinasjonshandboka\/vaksinasjon-ved-sykdom\/vaksinasjon-ved-medfodt-immunsvikt\/ Lest 19.9.2025."},{"key":"ref=3","unstructured":"Liu\u00a0Z, Liang\u00a0Q, Ren\u00a0Y et al. Immunosenescence: molecular mechanisms and diseases. Signal Transduct Target Ther 2023; 8: 200. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37179335&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fs41392-023-01451-2"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Memoli\u00a0MJ, Athota\u00a0R, Reed\u00a0S et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis 2014; 58: 214\u201324. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=24186906&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093%2Fcid%2Fcit725","DOI":"10.1093\/cid\/cit725"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Galmiche\u00a0S, Luong Nguyen\u00a0LB, Tartour\u00a0E et al. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. Clin Microbiol Infect 2022; 28: 163\u201377. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35020589&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.cmi.2021.09.036","DOI":"10.1016\/j.cmi.2021.09.036"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Chastain\u00a0DB, Spradlin\u00a0M, Ahmad\u00a0H et al. Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults. Clin Infect Dis 2024; 78: 811\u20132. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38598566&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1093%2Fcid%2Fciae129","DOI":"10.1093\/cid\/ciae129"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Wolf\u00a0AS, Ravussin\u00a0A, K\u00f6nig\u00a0M et al. T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis. JCI Insight 2023; 8: e165111. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37159281&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1172%2Fjci.insight.165111","DOI":"10.1172\/jci.insight.165111"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Riise\u00a0J, Meyer\u00a0S, Blaas\u00a0I et al. Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination. Br J Haematol 2022; 197: 697\u2013708. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35254660&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fbjh.18149","DOI":"10.1111\/bjh.18149"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"K\u00f6nig\u00a0M, Lorentzen\u00a0AR, Torgauten\u00a0HM et al. Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations. J Neurol Neurosurg Psychiatry 2023; 94: 19\u201322. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34670844&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136%2Fjnnp-2021-327612","DOI":"10.1136\/jnnp-2021-327612"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Oksbjerg\u00a0NR, Nielsen\u00a0SD, Blinkenberg\u00a0M et al. Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases. Mult Scler Relat Disord 2021; 52: 102988. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=33979772&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.msard.2021.102988","DOI":"10.1016\/j.msard.2021.102988"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Rajkumar\u00a0SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 2024; 99: 1802\u201324. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38943315&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fajh.27422","DOI":"10.1002\/ajh.27422"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Krajnc\u00a0N, Bsteh\u00a0G, Berger\u00a0T et al. Monoclonal Antibodies in the Treatment of Relapsing Multiple Sclerosis: an Overview with Emphasis on Pregnancy, Vaccination, and Risk Management. Neurotherapeutics 2022; 19: 753\u201373. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35378683&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007%2Fs13311-022-01224-9","DOI":"10.1007\/s13311-022-01224-9"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Ravi\u00a0G, Costa\u00a0LJ. Bispecific T-cell engagers for treatment of multiple myeloma. Am J Hematol 2023; 98: S13\u201321. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35702871&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fajh.26628","DOI":"10.1002\/ajh.26628"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Reynolds\u00a0G, Cliff\u00a0ERS, Mohyuddin\u00a0GR et al. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood Adv 2023; 7: 5898\u2013903. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37467036&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182%2Fbloodadvances.2023010539","DOI":"10.1182\/bloodadvances.2023010539"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Alirezaylavasani\u00a0A, Egner\u00a0IM, Dahl\u00a0B et al. Deficient SARS-CoV-2 hybrid immunity during inflammatory bowel disease. Clin Immunol 2025; 271: 110404. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39645159&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.clim.2024.110404","DOI":"10.1016\/j.clim.2024.110404"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Wolf\u00a0AS, Bj\u00f8rlykke\u00a0KH, \u00d8rbo\u00a0HS et al. T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study. EBioMedicine 2024; 108: 105317. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39260039&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.ebiom.2024.105317","DOI":"10.1016\/j.ebiom.2024.105317"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"J\u00f8rgensen\u00a0KK, H\u00f8ivik\u00a0ML, Chopra\u00a0A et al. Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type. Scand J Gastroenterol 2023; 58: 874\u201382. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36788656&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1080%2F00365521.2023.2177884","DOI":"10.1080\/00365521.2023.2177884"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"van Assen\u00a0S, Agmon-Levin\u00a0N, Elkayam\u00a0O et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414\u201322. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21131643&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1136%2Fard.2010.137216","DOI":"10.1136\/ard.2010.137216"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Kared\u00a0H, Alirezaylavasani\u00a0A, Lund\u00a0KP et al. Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipients. EBioMedicine 2023; 97: 104833. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37844534&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.ebiom.2023.104833","DOI":"10.1016\/j.ebiom.2023.104833"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Hovd\u00a0M, \u00c5sberg\u00a0A, Munthe\u00a0LA et al. Humoral vaccine response and breakthrough infections in kidney transplant recipients during the COVID-19 pandemic: a nationwide cohort study. EClinicalMedicine 2023; 60: 102035. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37362086&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.eclinm.2023.102035","DOI":"10.1016\/j.eclinm.2023.102035"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskelet Dis 2020; 12: 1759720X20936059.","DOI":"10.1177\/1759720X20936059"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"McNamara\u00a0LA, Topaz\u00a0N, Wang\u00a0X et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep 2017; 66: 734\u20137. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=28704351&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.15585%2Fmmwr.mm6627e1","DOI":"10.15585\/mmwr.mm6627e1"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Abid\u00a0MA, Abid\u00a0MB. SARS-CoV-2 vaccine response in CAR T-cell therapy recipients: A systematic review and preliminary observations. Hematol Oncol 2022; 40: 287\u201391. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34911142&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fhon.2957","DOI":"10.1002\/hon.2957"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Bishop\u00a0MR. Late complications and long-term care of adult CAR T-cell patients. Hematology (Am Soc Hematol Educ Program) 2024; 2024: 109\u201315. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=39643985&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182%2Fhematology.2024000534","DOI":"10.1182\/hematology.2024000534"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Federico\u00a0L, Tvedt\u00a0THA, Gainullin\u00a0M et al. Robust spike-specific CD4+ and CD8+ T cell responses in SARS-CoV-2 vaccinated hematopoietic cell transplantation recipients: a prospective, cohort study. Front Immunol 2023; 14: 1210899. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37503339&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3389%2Ffimmu.2023.1210899","DOI":"10.3389\/fimmu.2023.1210899"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Cordonnier\u00a0C, Einarsdottir\u00a0S, Cesaro\u00a0S et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 2019; 19: e200\u201312. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=30744963&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS1473-3099(18)30600-5","DOI":"10.1016\/S1473-3099(18)30600-5"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Syversen\u00a0SW, Jyssum\u00a0I, Tveter\u00a0AT et al. Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy. Arthritis Rheumatol 2022; 74: 1321\u201332. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35507355&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002%2Fart.42153","DOI":"10.1002\/art.42153"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"K\u00f6nig\u00a0M, Torgauten\u00a0HM, Tran\u00a0TT et al. Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination. JAMA Neurol 2022; 79: 307\u20139. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35072702&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1001%2Fjamaneurol.2021.5109","DOI":"10.1001\/jamaneurol.2021.5109"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Midtvedt\u00a0K, Vaage\u00a0JT, Heldal\u00a0K et al. Fourth dose of the SARS-CoV-2 vaccine in kidney transplant recipients with previously impaired humoral antibody response. Am J Transplant 2022; 22: 2704\u20136. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=35533010&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111%2Fajt.17091","DOI":"10.1111\/ajt.17091"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Jyssum\u00a0I, Kared\u00a0H, Tran\u00a0TT et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol 2022; 4: e177\u201387. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=34977602&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2FS2665-9913(21)00394-5","DOI":"10.1016\/S2665-9913(21)00394-5"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"\u00c5sberg\u00a0A, Hovd\u00a0M, Kjellevold\u00a0SA et al. Humoral Response After 6 or More Successive Doses of SARS-CoV-2 mRNA Vaccines in Kidney Transplant Recipients-Should We Keep Vaccinating? Transplantation 2023; 107: e279\u201380. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37496122&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1097%2FTP.0000000000004732","DOI":"10.1097\/TP.0000000000004732"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"de la C\u00e1mara R, Meisel R, Vaccinations I et al. red. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies. Cham: Springer, 2024.","DOI":"10.1007\/978-3-031-44080-9_29"},{"key":"ref=33","unstructured":"Buchan\u00a0CA, Agbayani\u00a0G, Hueniken\u00a0K et al. Immunogenicity and Safety of Third, Fourth, and Subsequent COVID-19 Vaccine Doses in Recipients of Hematopoietic Cell Transplantation and Cellular Therapy. Transplant Cell Ther 2025; PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=41213500&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016%2Fj.jtct.2025.10.037"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Alnaimat\u00a0F, Sweis\u00a0JJG, Jansz\u00a0J et al. Vaccination in the Era of Immunosuppression. Vaccines (Basel) 2023; 11: 1446. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37766123&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.3390%2Fvaccines11091446","DOI":"10.3390\/vaccines11091446"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Otero-Romero\u00a0S, Lebrun-Fr\u00e9nay\u00a0C, Reyes\u00a0S et al. ECTRIMS\/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Mult Scler 2023; 29: 904\u201325. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=37293841&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1177%2F13524585231168043","DOI":"10.1177\/13524585231168043"},{"key":"ref=36","unstructured":"Folkehelseinstituttet. Vaksinasjonsh\u00e5ndboka. https:\/\/www.fhi.no\/va\/vaksinasjonshandboka\/ Lest 20.2.2026."},{"key":"ref=37","unstructured":"Tran TT, Vaage EB, Mehta A et al. Titers of antibodies the receptor-binding domain (RBD) of ancestral SARS-CoV-2 are predictive for levels of neutralizing antibodies to multiple variants. bioRxiv. Preprint 13.4.2022. https:\/\/www.biorxiv.org\/content\/10.1101\/2022.03.26.484261v2 LEst 20.2.2026."},{"key":"ref=38","unstructured":"Christensen\u00a0IE, Jyssum\u00a0I, Tveter\u00a0AT et al. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study. BMC Med 2022; 20: 378. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=36199139&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1186%2Fs12916-022-02587-8"},{"key":"ref=39","unstructured":"Curran\u00a0D, Doherty\u00a0TM, Lecrenier\u00a0N et al. Healthy ageing: Herpes zoster infection and the role of zoster vaccination. NPJ Vaccines 2023; 8: 184. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=38017011&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038%2Fs41541-023-00757-0"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Vielot\u00a0NA, Jonsson Funk\u00a0M, St\u00fcrmer\u00a0T et al. Effectiveness of Recombinant Herpes Zoster Vaccine in the U.S. Medicare Population, 2018 to 2019, by Immunocompetence and Prior Receipt of Live Zoster Vaccine. Ann Intern Med 2025; 178: 1728\u201336. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=41082726&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.7326%2FANNALS-24-02409","DOI":"10.7326\/ANNALS-24-02409"},{"key":"ref=41","unstructured":"Folkehelseinstituttet. Hepatitt B-vaksine og hepatitt B-immunglobulin \u2013 h\u00e5ndbok for helsepersonell. https:\/\/www.fhi.no\/va\/vaksinasjonshandboka\/vaksiner-mot-de-enkelte-sykdommene\/hepatitt-b-vaksinasjon-og-immunglobulin\/#indikasjoner-og-mlgrupper Lest 3.2.2026."},{"key":"ref=42","unstructured":"Folkehelseinstituttet. Meningokokkvaksine \u2013 h\u00e5ndbok for helsepersonell. https:\/\/www.fhi.no\/va\/vaksinasjonshandboka\/vaksiner-mot-de-enkelte-sykdommene\/meningokokkvaksinasjon\/ Lest 3.2.2026."},{"key":"ref=43","unstructured":"Folkehelseinstituttet. Varicellavaksine (vannkopper) og varicella-zoster immunglobulin \u2013 h\u00e5ndbok for helsepersonell. https:\/\/www.fhi.no\/va\/vaksinasjonshandboka\/vaksiner-mot-de-enkelte-sykdommene\/aricellavaksine-og-varicella-zoster-immunglobulin\/#indikasjoner-og-mlgrupper Lest 3.2.2026."},{"key":"ref=44","unstructured":"Folkehelseinstituttet. HPV-vaksine (Humant papillomavirus) \u2013 h\u00e5ndbok for helsepersonell. https:\/\/www.fhi.no\/va\/vaksinasjonshandboka\/vaksiner-mot-de-enkelte-sykdommene\/hpv-vaksinasjon\/#indikasjoner-og-mlgrupper Lest 3.2.2026."}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":["Vaksinering av immunsupprimerte personer"],"language":"no","deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:15:32Z","timestamp":1789740932000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2026\/04\/klinisk-oversikt\/vaksinering-av-immunsupprimerte-personer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,4,21]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.25.0555","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]}}}